Skip to contentH
Hepion Pharmaceuticals, Inc.
H
HEPAHepion Pharmaceuticals, Inc. Q3 2022 · 10-Q
Revenue$0.00$0.00— vs Q3 2021 Net Income-$8.55M-$8.55MN/M vs Q3 2021 EPS Diluted-$2.24-$2.24N/M vs Q3 2021 Operating Income-$8,465,326N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$12,534,357N/M ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end